{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:22:35Z","timestamp":1791138155593,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1007\/s10637-005-1157-4","type":"journal-article","created":{"date-parts":[[2005,7,20]],"date-time":"2005-07-20T22:59:28Z","timestamp":1121900368000},"page":"569-575","source":"Crossref","is-referenced-by-count":83,"title":["Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma"],"prefix":"10.1007","volume":"23","author":[{"given":"D Scott","family":"Ernst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Eisenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Wainman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Lohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Baetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Belanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Smylie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"1157_CR1","unstructured":"Canadian Cancer Statistics 2003. Toronto, Canada, 2003"},{"key":"1157_CR2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.1998.16.3.1103","volume":"16","author":"O Eton","year":"1998","unstructured":"Eton O, Legha S, Moon T, Buzaid A, Papadopoulos NE, Plager C, Burgess A, Bedikian AY, Ring S, Dong Q, Glassman AB, Balch CM, Benjamin RS: Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16: 1103\u20131111, 1998","journal-title":"J Clin Oncol"},{"key":"1157_CR3","unstructured":"Balch C, Reintgen D, Kirkwood J, Cutaneous Melanoma. In: DeVita V, Hellman S, Rosenberg S (eds): Cancer: Principles and Practice of Oncology, 1997, pp 1947\u20131994"},{"key":"1157_CR4","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.1993.11.10.1969","volume":"11","author":"J Sparano","year":"1993","unstructured":"Sparano J, Fisher R, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins M, Dutcher J, Micetich K, Weiss G: Randomized phase III trial of treatment with high dose interleukin-II either alone or in combination with interferon alpha-2a in patients with advanced melanoma. J Clin Oncol 11: 1969\u20131977, 1993","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"1157_CR5","first-page":"S11","volume":"6","author":"M Atkins","year":"2000","unstructured":"Atkins M, Kunkel L, Sznol M, Rosenberg SA: High dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long term survival update. Cancer J Sci Am 6(suppl 1): S11\u2013S14, 2000","journal-title":"Cancer J Sci Am"},{"key":"1157_CR6","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1200\/JCO.2002.07.044","volume":"20","author":"O Eton","year":"2002","unstructured":"Eton O, Legha S, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring S, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20: 2045\u20132052, 2002","journal-title":"J Clin Oncol"},{"key":"1157_CR7","first-page":"419","volume":"1","author":"R Habalan","year":"1998","unstructured":"Habalan R, Miglarses M, Smicun Y, Puig S: Melanoma from the cell cycle point of view (review). Int J Mol Med 1: 419\u2013425, 1998","journal-title":"Int J Mol Med"},{"key":"1157_CR8","first-page":"5475","volume":"56","author":"J Bartova","year":"1996","unstructured":"Bartova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J: The p16-cyclin D\/Cdk-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 56: 5475\u20135483, 1996","journal-title":"Cancer Res"},{"key":"1157_CR9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0005-2760(97)00163-X","volume":"1390","author":"G Arthur","year":"1999","unstructured":"Arthur G, Bittman R: The inhibition of cell signaling pathways by antitumor ether lipids. Biochem Biophys Acta 1390: 85\u2013102, 1999","journal-title":"Biochem Biophys Acta"},{"key":"1157_CR10","first-page":"27","volume":"23","author":"A Leroy","year":"2003","unstructured":"Leroy A, de Bruyne GK, Oomen LC, Mareel MM: Alkylphospholipids reversibly open epithelial tight junctions. Anticancer Res 23: 27\u201332, 2003","journal-title":"Anticancer Res"},{"key":"1157_CR11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1158\/0008-5472.CAN-03-2505","volume":"64","author":"SA De","year":"2004","unstructured":"De SA, Marinissen M, Diggs J, Wang XF, Pages G, Senderowicz A: Transcriptional activation of p21(waf1\/cip1) by alkylphospholipids: role of the mitogen-activated protein kinase pathway in the transactivation of the human p21(waf1\/cip1) promoter by Sp1. Cancer Res 64: 743\u2013750, 2004","journal-title":"Cancer Res"},{"key":"1157_CR12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/jnci\/72.1.53","volume":"72","author":"R Andreesen","year":"1984","unstructured":"Andreesen R, Osterholz J, Luckenbach GA, Costabel U, Schulz A, Speth V, Munder PG, Lohr GW: Tumor cytotoxicity of human macrophages after incubation with synthetic analogues of 2-lysophosphatidylcholine. JNCI 72: 53\u201359, 1984","journal-title":"JNCI"},{"key":"1157_CR13","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/BF02535544","volume":"22","author":"E Fleer","year":"1987","unstructured":"Fleer E, Under C, Kim D, Eibl H: Metabolism of ether phospholipids and analogs in neoplastic cells. Lipids 22: 856\u2013861, 1987","journal-title":"Lipids"},{"key":"1157_CR14","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0959-8049(97)89020-X","volume":"33","author":"P Hilgard","year":"1997","unstructured":"Hilgard P, Klenner T, Stekar J, Nossner G, Kutscher B, Engel J: D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer 33: 442\u2013446, 1997","journal-title":"Eur J Cancer"},{"key":"1157_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0006-2952(01)00715-8","volume":"62","author":"M Rybczynska","year":"2001","unstructured":"Rybczynska M, Spitaler M, Knebel NG, Boeck G, Grunicke H, Hofmann J: Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. Biochem Pharmacol 62: 765\u2013772, 2001","journal-title":"Biochem Pharmacol"},{"key":"1157_CR16","first-page":"1093","volume":"2","author":"SB Kondapaka","year":"2003","unstructured":"Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK: Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2: 1093\u20131103, 2003","journal-title":"Mol Cancer Ther"},{"key":"1157_CR17","first-page":"1401","volume":"62","author":"V Patel","year":"2002","unstructured":"Patel V, Lahusen T, Sy T, Sausville EA, Gutkind JS, Senderowicz AM: Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res 62: 1401\u20131409, 2002","journal-title":"Cancer Res"},{"key":"1157_CR18","unstructured":"Perifosine Investigator Brochure, 1998. Zentaris AG, AOI Pharmaceuticals."},{"key":"1157_CR19","unstructured":"Unger, C. Study D-21266-3040. AOI Phase 1 Study Group. Unpublished Data"},{"key":"1157_CR20","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/S0959-8049(02)00127-2","volume":"38","author":"M Crul","year":"2002","unstructured":"Crul M, Rosing H, de Klerk GJ, Dubbelman R, Traiser M, Reichert S, Knebel NG, Schellens JH, Beijnen JH, ten Bokkel Huinink WW: Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 38: 1615\u20131621, 2002","journal-title":"Eur J Cancer"},{"key":"1157_CR21","unstructured":"Unger, C. Study D-21266-3087. Weekly enteric coated tablets. AOI Phase 1 Study Group. Unpublished Data"},{"key":"1157_CR22","first-page":"1837","volume":"21","author":"M Monga","year":"2002","unstructured":"Monga M, Messmann RA, Headlee D, Woo EW, Figg WD, Muro A, Sausville EA: A Phase I trial of oral perifosine in patients with refractory neoplasms. Proc Am Soc Clin Oncol 21: abstract 1837, 2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"1157_CR23","unstructured":"Wilding, G: NCI Trial at the University of Wisconsin, 2000. Unpublished Data"},{"key":"1157_CR24","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2001.19.3.785","volume":"19","author":"S Dent","year":"2001","unstructured":"Dent S, Zee B, Dancey J, Hanauske A, Wanders J, Eisenhauer E: Application of a new multinomial phase II stopping rule using response and early progression. J Clin Oncol 19: 785\u2013791, 2001","journal-title":"J Clin Oncol"},{"key":"1157_CR25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.2002.20.2.599","volume":"20","author":"B Freidlin","year":"2002","unstructured":"Freidlin B, Dancey J, Korn E, Zee B, Eisenhauer E: Multinomial phase II trial designs. J Clin Oncol 20: 599, 2002","journal-title":"J Clin Oncol"},{"key":"1157_CR26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasses","year":"2000","unstructured":"Therasses P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom A, Christian M, Gwyther S: New guidelines to evaluate the response to treatments in solid tumors (RECIST guidelines). J Natl Cancer Inst 92: 205\u2013216, 2000","journal-title":"J Natl Cancer Inst"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-005-1157-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-005-1157-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-005-1157-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-005-1157-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:03:31Z","timestamp":1678557811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-005-1157-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["1157"],"URL":"https:\/\/doi.org\/10.1007\/s10637-005-1157-4","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}